Indocyanine Green-based Glow Nanoparticles Probe for Cancer Imaging.
deep tissue bioimaging
indocyanine green
nanoparticle probes
nanoparticles
near infra-red fluorescent cancer imaging
Journal
Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
08
2022
accepted:
22
03
2023
medline:
9
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Indocyanine green (ICG) is one of the FDA-approved near infra-red fluorescent (NIRF) probes for cancer imaging and image-guided surgery in the clinical setting. However, the limitations of ICG include poor photostability, high concentration toxicity, short circulation time, and poor cancer cell specificity. To overcome these hurdles, we engineered a nanoconstruct composed of poly (vinyl pyrrolidone) (PVP)-indocyanine green that is cloaked self-assembled with tannic acid (termed as indocyanine green-based glow nanoparticles probe, ICG-Glow NPs) for the cancer cell/tissue-specific targeting. The self-assembled ICG-Glow NPs were confirmed by spherical nanoparticles formation (DLS and TEM) and spectral analyses. The NIRF imaging characteristic of ICG-Glow NPs was established by superior fluorescence counts on filter paper and chicken tissue. The ICG-Glow NPs exhibited excellent hemo and cellular compatibility with human red blood cells, kidney normal, pancreatic normal, and other cancer cell lines. An enhanced cancer-specific NIRF binding and imaging capability of ICG-Glow NPs was confirmed using different human cancer cell lines and human tumor tissues. Additionally, tumor-specific binding/accumulation of ICG-Glow NPs was confirmed in MDA-MB-231 xenograft mouse model. Collectively, these findings suggest that ICG-Glow NPs have great potential as a novel and safe NIRF imaging probe for cancer cell/tumor imaging. This can lead to a quicker cancer diagnosis facilitating precise disease detection and management.
Identifiants
pubmed: 37151801
doi: 10.7150/ntno.78405
pii: ntnov07p0353
pmc: PMC10161388
doi:
Substances chimiques
Indocyanine Green
IX6J1063HV
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-367Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM139727
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Antibodies (Basel). 2020 Jul 20;9(3):
pubmed: 32698317
J Fluoresc. 2010 May;20(3):681-93
pubmed: 20213244
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
ACS Appl Bio Mater. 2022 Mar 21;5(3):1104-1119
pubmed: 35179871
Pharmaceutics. 2018 Aug 01;10(3):
pubmed: 30071698
J Clin Oncol. 2010 Jul 10;28(20):3366-79
pubmed: 20530283
Geburtshilfe Frauenheilkd. 2018 Jan;78(1):54-62
pubmed: 29375146
Int J Nanomedicine. 2019 Sep 03;14:7107-7121
pubmed: 31564868
Lab Anim (NY). 2007 Sep;36(8):40-3
pubmed: 17721532
Mol Imaging. 2009 Dec;8(6):341-54
pubmed: 20003892
Curr Protoc Cytom. 2012 Apr;Chapter 12:Unit12.27
pubmed: 22470154
ACS Biomater Sci Eng. 2016 Dec 12;2(12):2294-2303
pubmed: 28944286
Acta Pharm Sin B. 2018 Jul;8(4):602-614
pubmed: 30109184
Sci Rep. 2018 Apr 27;8(1):6647
pubmed: 29703912
Macromol Biosci. 2016 Dec;16(12):1815-1823
pubmed: 27735135
J Thorac Cardiovasc Surg. 2006 Sep;132(3):585-94
pubmed: 16935114
J Anaesthesiol Clin Pharmacol. 2010 Oct;26(4):517-20
pubmed: 21547182
J Visc Surg. 2014 Apr;151(2):117-24
pubmed: 24461273
ACS Appl Bio Mater. 2020 Apr 20;3(4):2344-2349
pubmed: 32455339
Int J Nanomedicine. 2014 Mar 05;9:1347-65
pubmed: 24648733
Biotechnol Adv. 2016 Sep-Oct;34(5):768-789
pubmed: 27090752
Mol Imaging. 2003 Oct;2(4):303-12
pubmed: 14717329
Biochim Biophys Acta. 2013 Jul;1831(7):1260-6
pubmed: 24046866
J Colloid Interface Sci. 2019 Feb 1;535:133-148
pubmed: 30292104
ACS Omega. 2022 Jun 28;7(27):23939-23949
pubmed: 35847334
Future Oncol. 2009 Nov;5(9):1501-11
pubmed: 19903075
J Pharm Sci. 2016 Oct;105(10):3143-3152
pubmed: 27522526
Pharmaceutics. 2021 Dec 22;14(1):
pubmed: 35056911
Front Chem. 2020 Jul 16;8:535
pubmed: 32766203
Int J Nanomedicine. 2019 Sep 25;14:7823-7838
pubmed: 31576126
ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38537-38554
pubmed: 31553876
ACS Appl Bio Mater. 2022 Aug 17;:
pubmed: 35976626
Bioconjug Chem. 2016 Oct 19;27(10):2225-2238
pubmed: 27547843
J Surg Oncol. 2018 Aug;118(2):283-300
pubmed: 29938401
ACS Appl Mater Interfaces. 2021 Jan 27;13(3):3694-3700
pubmed: 33442969
ACS Biomater Sci Eng. 2019 May 13;5(5):2343-2354
pubmed: 33405784
J Biochem. 2006 Mar;139(3):495-502
pubmed: 16567414
Int J Nanomedicine. 2011;6:2779-90
pubmed: 22128249
Clin Ophthalmol. 2020 Jan 20;14:171-178
pubmed: 32021082
Mol Imaging Biol. 2023 Feb;25(1):144-155
pubmed: 34888759
Pharmaceutics. 2021 May 31;13(6):
pubmed: 34072719
J Neurooncol. 2020 Sep;149(2):243-252
pubmed: 32914293
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Theranostics. 2018 Feb 2;8(5):1227-1242
pubmed: 29507616
Curr Opin Chem Biol. 2010 Feb;14(1):64-70
pubmed: 19926332
Proc SPIE Int Soc Opt Eng. 2020 Feb;11222:
pubmed: 32255887
Colloids Surf B Biointerfaces. 2016 Aug 1;144:8-20
pubmed: 27058278
Int J Mol Sci. 2020 Nov 30;21(23):
pubmed: 33266216
Biomaterials. 2015 Apr;46:1-12
pubmed: 25678111
PLoS One. 2014 Jul 29;9(7):e103342
pubmed: 25072388
Gynecol Oncol. 2012 Oct;127(1):126-30
pubmed: 22796548
Nucl Med Commun. 2012 Apr;33(4):349-61
pubmed: 22314804